Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification

Ossification, Heterotopic Clinical Trial

Official title: Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial

Status Recruiting

Clinical Trial Summary

Hypotheses:

H1: Celecoxib, when given less than five days after injury will result in a statistical decrease in the incidence and/or severity of radiographically apparent Heterotopic Ossification when compared to controls.

H2a: A biomarker profile will accurately predict which patients in the treatment group will respond to Celecoxib prophylaxis for Heterotopic Ossification.

H2b: A biomarker profile will accurately predict which patients in the control group are at highest risk of developing Heterotopic Ossification

Clinical Trial Description

This study is a prospective, randomized, controlled clinical trial. ;

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Ossification, Heterotopic

• NCT number: NCT01631669
• Study type: Interventional
• Source: Walter Reed National Military Medical Center
• Contact: Jonathan A Forsberg, MD
• Phone: 301-319-3403
• Email: jonathan.forsberg@med.navy.mil
• Status: Recruiting
• Phase: N/A
• Start date: May 2012
• Completion date: June 2018